Combining select neuropsychological assessment with blood-based biomarkers to detect mild Alzheimer's disease: A molecular neuropsychology approach

Journal of Alzheimer's Disease

Volumn 42, Issue 2, 2014, Pages 635-640

  Edwards, Melissa ^a   Balldin, Valerie Hobson ^b   Hall, James ^c,d   O'Bryant, Sid ^d  

^a UNIVERSITY OF NORTH TEXAS   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^c University of North Texas Health Science Center   (United States)

^d UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

Alzheimer's disease; biomarkers; molecular; neuropsychology

Indexed keywords

INTERLEUKIN 7; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER;

AGED; ALZHEIMER DISEASE; ARTICLE; ASSAY; CHEMOLUMINESCENCE; CLINICAL DEMENTIA RATING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; ELECTROCHEMILUMINESCENCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD ALZHEIMER DISEASE; MINI MENTAL STATE EXAMINATION; NEUROPSYCHOLOGICAL TEST; NEUROPSYCHOLOGY; PREDICTOR VARIABLE; PSYCHOLOGIC TEST; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; BLOOD; COGNITION DISORDERS; COMPLICATION; PSYCHOLOGICAL RATING SCALE; STATISTICAL MODEL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BIOMARKERS; COGNITION DISORDERS; FEMALE; HUMANS; LOGISTIC MODELS; MALE; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; SENSITIVITY AND SPECIFICITY;

EID: 84916940971     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-140852     Document Type: Article

References (28)

1. Alzheimer's Association (2012) Alzheimer's Disease Facts and Figures. Alzheimers Dement 8, 1-72.
2. Blennow K, Vanmechelen E, Hampel H (2001) CSF total tau, AB42 and phosphorylated tau protein as biomarkers for Alzheimer's disease. Mol Neurobiol 24, 87-97.
3. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 263-269.
4. Ray S, Britschqi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, Friedman LF, Galasko DR, Jutel M, Karydas A, Kaye JA, Leszek J, Miller BL, Minthon L, Quinn JF, Rabinovici GD, Robinson WH, Sabbagh MN, So YT, Sparks DL, Tabaton M, Tinklenberg J, Yesavage JA, Tibshirani R, Wyss-Coray T (2007) Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 13, 1359-1362.
5. O'Bryant SE, Xiao G, Barber R, Reisch J, Hall J, Cullum CM, Doody R, Fairchild T, Adams P, Wilhelmsen K, Diaz- Arrastia R for the Texas Alzheimer's Research and Care Consortium (2011) A blood-based algorithm for the detection of Alzheimer's disease. Dement Geriatr Cogn Disord 32, 55-62.
6. O'Bryant SE, Xiao G, Zhang F, Edwards M, German D, Yin X, Como T, Reisch J, Huebinger R, Graff-Radford N, Dickson D, Barber R, Hall J, O'Suilleabhain P, Grammas P (2014) Validation of a serum screen for Alzheimer's disease across platforms, species and tissues. J Alzheimers Dis. doi: 10.3233/JAD-141041
7. O'Bryant SE, Xiao G, Barber R, Cullum CM, Weiner M, Hall J, Edwards M, Grammas P, Wilhelmsen K, Doody R, Diaz-ArrastiaR(2013) Molecular neuropsychology: Creation of test-specific blood based biomarker algorithms. Dement Geriatr Cogn Disord 37, 45-57.
8. Elkelenboom P, Veerhuis R, van Exel E, Hoozemans JJ, Rozemuller AJ, van Gool WA (2011) The early involvement of the innate immunity in the pathogenesis of late-onset Alzheimer's disease: Neuropathological, epidemiological and genetic evidence. Curr Alzheimer Res 8, 143-150.
9. Grammas P (2011) Neurovascular dysfunction, inflammation and endothelial activation: Implications for the pathogenesis of Alzheimer's disease. J Neuroinflammatio 8, 26.
10. Tobinick E (2009) Tumour necrosis factor modulation for treatment of Alzheimer's disease: Rationale and current evidence. CNS Drugs 23, 713-725.
11. Tarkowski E, Blennow K, Wallin A, Tarkowski A (1999) Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia. J Clin Immunol 19, 223-230.
12. Cacabelos R, Alvarez XA, Franco-Maside A, Fernandez- Novoa L, Caamano J (1994) Serum tumor necrosis factor (TNF) in Alzheimer's disease and multi-infarct dementia. Exp Clin Pharmacol 16, 29-35.
13. De Luigi A, Fragiacomo C, Lucca U, Quadri P, Tettamanti M, Garzia De Simoni M (2001) Inflammatory markers in Alzheimer's disease and multi-infarct dementia. Mech Ageing Dev 122, 1985-1995.
14. Jiang Q, Li WQ, Aiello FB, Mazzucchelli R, Asefa B, Khaled AR, Durum SK (2005) Cell biology of IL-7, a key lymphotrophin. Cytokine Growth Factor Rev 16, 513-533.
15. Furney SJ, Kronenberg D, Simmons A, Guntert A, Dobson RJ, Proitsi P,Wahlund LO, Kloszewska I, Mecocci P, Soininen H, Tsolaki M, Vellas B, Spenger C, Lovestone S (2011) Combinatorial markers of mild cognitive impairment conversion to Alzheimer's disease-cytokines and MRI measures together predict disease progression. J Alzheimers Dis 26, 395-405.
16. Agrell B, DehlinO(1998) The clock-drawing test. AgeAgeing 27, 399-403.
17. Shulman K (2000) Clock-drawing. Is it the ideal cognitive screening test? Int J Geriatr Psychiatry 15, 548-561.
18. Sunderland T, Hill JL, Mellow AM, Lawlor BA, Gundersheimer J, Newhouse PA, Grafman JH (1989) Clock drawing in Alzheimer's disease:Anovel measure of dementia severity. J Am Geriatr Soc 37, 725-729.
19. Wolf-Klein GP, Silverstone FA, Levy AP, Breuer J, Brod MS (1989) Screening for Alzheimer's disease by clock drawing. J Am Geriatr Soc 37, 730-734.
20. Royall DR, Mulroy AR, Chiodo LK, Polk MJ (1999) Clock drawing is sensitive to executive control: A comparison of six methods. J Gerontol B Psychol Sci Soc Sci 54, P328-P333.
21. Powlishta KK, Von Dras DD, Stanford A, Carr DB, Tsering C, Miller JP, Morris JC (2002) The clock drawing test is a poor screen for very mild dementia. Neurology 59, 898-903.
22. McKhann D, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
23. Lezak MS, Howieson DB, Loring DW (2004) Neuropsychological Assessment, 4th edition, Oxford University Press, Oxford.
24. Strauss E, Sherman EMS, SpreenO(2006)ACompendium of Neuropsychological Tests: Administration, Norms, and Commentary, 3rd edition, Oxford University Press, Oxford.
25. Wechsler D (1997)Wechsler Memory Scale, 3rd edition, The Psychological Corporation, San Antonio.
26. Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, AdeyM, Leirer VO (1983) Development and validation of a geriatric depression screening scale: A preliminary report. J Psychiatr Res 17, 37-49.
27. Folstein MF, Folstein SE, McHugh PR (1975) 'Mini-Mental State': A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.
28. Morris JC (1993) The Clinical Dementia Rating (CDR): Current version and scoring rules (see comment). Neurology 43, 2412-2414.